Dilution is a central concern for biotech investors. The basic issue at hand is that developmental-stage or early commercial-stage biotechs rely heavily on dilution to raise the massive amount of ...

The shortcomings of SAFE notes (simple agreement for future equity) are coming home to roost; ironically, entrepreneurs are paying the price. Y Combinator invented the notes with a noble goal: “we ...